Probing the pharmacology of the 5-HT1B receptor and its role in pulmonary disease

Lead Research Organisation: University of Glasgow
Department Name: School of Life Sciences


Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.


10 25 50
Description 5HT1B antagonist can reverse pulmonary hypertension
Exploitation Route Development of a 5HT1B antagonist for pulmonary hypertension
Sectors Pharmaceuticals and Medical Biotechnology

Description MRC project grant
Amount £595,086 (GBP)
Funding ID MR/N011112/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 05/2016 
End 04/2019
Description 5HT1B antagonists in PAH 
Organisation University of Cambridge
Department Cambridge Enterprise
Country United Kingdom 
Sector Academic/University 
PI Contribution Results of BBSRC Follow on Funds
Collaborator Contribution Research
Impact n/a
Start Year 2010
Description miR96 and pulmonary hypertension 
Organisation United Therapeutics
Country United States 
Sector Academic/University 
PI Contribution Building on our success with the MRC CiC award and the PhD studentship we were awarded a MRC project grant to further our studies into miR96 and PAH. This created discussions with United Therapeutics who supplemented tis study.
Collaborator Contribution Provision of £79000 to cover costs of a patent and RNAseq
Impact Too early
Start Year 2016